Stephen C. Mack, Cleveland Clinic, Cleveland, OH; and Paul A. Northcott, St Jude Children's Research Hospital, Memphis, TN.
J Clin Oncol. 2017 Jul 20;35(21):2346-2354. doi: 10.1200/JCO.2017.72.9921. Epub 2017 Jun 22.
Recent breakthroughs in next-generation sequencing technology and complementary genomic platforms have transformed our capacity to interrogate the molecular landscapes of human cancers, including childhood brain tumors. Numerous high-throughput genomic studies have been reported for the major histologic brain tumor entities diagnosed in children, including interrogations at the level of the genome, epigenome, and transcriptome, many of which have yielded essential new insights into disease biology. The nature of these discoveries has been largely platform dependent, exemplifying the usefulness of applying different genomic and computational strategies, or integrative approaches, to address specific biologic and/or clinical questions. The goal of this article is to summarize the spectrum of molecular profiling methods available for investigating genomic aspects of childhood brain tumors in both the research and the clinical setting. We provide an overview of the main next-generation sequencing and array-based technologies currently being applied in this field and draw from key examples in the recent neuro-oncology literature to illustrate how these genomic approaches have profoundly advanced our understanding of individual tumor entities. Moreover, we discuss the current status of genomic profiling in the clinic and how different platforms are being used to improve patient diagnosis and stratification, as well as to identify actionable targets for informing molecularly guided therapies, especially for patients for whom conventional standard-of-care treatments have failed. Both the demand for genomic testing and the main challenges associated with incorporating genomics into the clinical management of pediatric patients with brain tumors are discussed, as are recommendations for incorporating these assays into future clinical trials.
近年来,下一代测序技术和互补基因组平台的突破,改变了我们研究人类癌症分子图谱的能力,包括儿童脑肿瘤。已经有许多高通量基因组研究针对儿童诊断的主要组织学脑肿瘤实体进行了报道,包括对基因组、表观基因组和转录组水平的研究,其中许多研究为疾病生物学提供了重要的新见解。这些发现的性质在很大程度上取决于研究平台,这证明了应用不同的基因组和计算策略或综合方法来解决特定的生物学和/或临床问题的有用性。本文的目的是总结可用于研究儿童脑肿瘤基因组方面的分子分析方法的范围,包括研究和临床环境。我们概述了目前在该领域应用的主要下一代测序和基于阵列的技术,并从最近神经肿瘤学文献中的关键实例中汲取经验,说明这些基因组方法如何深刻地提高了我们对单个肿瘤实体的理解。此外,我们还讨论了基因组分析在临床中的现状,以及不同平台如何用于改善患者的诊断和分层,以及确定可用于指导分子治疗的可操作靶点,特别是对于那些常规标准治疗失败的患者。讨论了对基因组检测的需求以及将基因组学纳入儿科脑肿瘤患者临床管理中相关的主要挑战,并为将这些检测纳入未来临床试验提出了建议。